skip to Main Content

[Etoday] C&R Research “Neurobiogen obesity treatment, U.S. FDA Pre-IND application”

C&R Research announced on the 25th that it has decided to submit a Phase 2 Pre-IND (pre-meeting) application to the U.S. Food and Drug Administration (FDA) for Neurobiogen’s dementia and obesity treatment drug ‘KDS2010’. C&R Research has been conducting phase 1 clinical trials of Neurobiogen’s KDS2010 in Korea. As an extension of this, it was explained that this time, it was decided to conduct Pre-IND with the goal of phase 2 clinical trials in the United States.


An official from C&R Research said, “This will be an opportunity for C&R Research to advance into the global market as we will be carrying out direct work on regulatory affairs (RA) with Neurobiogen.”


<View original article>



Back To Top